**
In a significant move reflecting heightened scrutiny over safety practices, a chain of private plasma donation centres in Canada has announced a temporary suspension of collections. This decision follows the tragic deaths of two donors, including 22-year-old Rodiyat Alabede, and coincides with an ongoing investigation by Health Canada into potential regulatory violations. The implications of these events could reshape the landscape of plasma donation in the country and raise critical questions about donor safety.
Donor Deaths Prompt Regulatory Action
Grifols, the Spanish healthcare firm operating the only private plasma donation clinics in Canada, confirmed the halt in collections on Wednesday. This decision came shortly after Health Canada issued a notice of non-compliance, citing the clinic’s failure to adhere to established blood donation regulations. The ministry’s investigation revealed alarming circumstances surrounding the two fatalities, which occurred in Manitoba—one in October 2025 and another in January 2026.
Although Health Canada has not disclosed the identities of the deceased, advocates and friends have identified Alabede as one of the donors. Described as an aspiring social worker and an international student, she reportedly experienced distress during the donation process on October 25. An autopsy revealed that Alabede’s death was attributed to cardiac arrest occurring shortly after her plasma donation. However, Health Canada has stated that there was “no link” between her death and the donation itself.
Safety Concerns and Allegations
The circumstances surrounding Alabede’s donation have raised serious concerns among patient advocates, particularly regarding the adequacy of pre-donation screening processes. Kat Lanteigne, a representative of Alabede’s family and a safe blood campaigner, has alleged that staff at the clinic lacked proper training in plasma extraction techniques. “The failures were so egregious that … now we have more questions than answers,” Lanteigne stated, underscoring the urgency for a thorough investigation into the practices at Grifols clinics.
In response to these concerns, advocates are calling for a comprehensive inquest into Alabede’s death. They point out discrepancies between the autopsy findings and the summary provided by Health Canada, suggesting that significant medical inconsistencies warrant further examination.
Findings from Health Canada’s Investigation
Health Canada’s inspection reports have unveiled a range of deficiencies at Grifols clinics, particularly at the Taylor Avenue location in Winnipeg. Issues cited include inadequate staff training, lapses in standard operating procedures, and poor record-keeping practices. Alarmingly, inspectors noted instances where plasma collections were not halted despite alarm signals from medical equipment.
In light of these findings, Health Canada has reassured the public that the safety and security of Canada’s overall blood and plasma supply remain uncompromised. Grifols, in its defence, has stated that the decision to pause collections is a proactive measure taken to address what it describes as “unfounded attention” surrounding the clinics.
The Role of Plasma in Healthcare
Plasma, a yellowish liquid component of blood, plays a crucial role in various medical treatments. It facilitates the transport of red and white blood cells and platelets, aids in preventing excessive bleeding, and is essential for creating medications for conditions such as haemophilia, liver disease, and certain cancers. The plasma donation process, which involves the use of an apheresis machine, is notably different from standard blood donation, taking approximately 90 minutes to complete.
In Canada, the regulation of paid plasma clinics varies by province. While Manitoba permits such practices, provinces like British Columbia and Quebec have banned them altogether. This regulatory inconsistency has implications for donor safety and public health, particularly in light of the recent incidents.
Why it Matters
The decision to suspend plasma collections not only reflects immediate safety concerns but also highlights broader issues regarding the regulation of private healthcare practices in Canada. The scrutiny surrounding Grifols could prompt a reevaluation of safety standards and donor protocols across the country, potentially leading to reforms that better protect individuals who choose to donate. As the investigation unfolds, the health and wellbeing of donors must remain a priority, ensuring that tragedies like those experienced by Alabede and her family do not recur.
